98%
921
2 minutes
20
Studies of spontaneous extrapyramidal symptoms, dyskinesia and parkinsonism, in unmedicated schizophrenia are of importance in understanding their underlying pathology and relation to the psychosis. This is a study of extrapyramidal symptoms using Abnormal Involuntary Movements Scale for dyskinesia and Simpson-Angus Scale for parkinsonism in 143 schizophrenia patients who never received antipsychotic medication. Psychopathology was measured using the Positive and Negative Syndrome Scale. Dyskinesia was present in 35% of patients and parkinsonism in 15%. The two disorders coexisted in 11 subjects. Orofacial dyskinesia, rigidity and tremor were common symptoms noted. There was no significant change in the rates and total scores of dyskinesia and parkinsonism with gender, age, duration of illness or age at onset of psychosis. Dyskinesia was unrelated to psychopathology. Parkinsonism score correlated positively with the motor symptom cluster of psychopathology. Dyskinesia and parkinsonism scores correlated positively with each other and parkinsonism score discriminated presence of dyskinesia. The associations between the spontaneous abnormal movements and other aspects of schizophrenia differed from those described in treated patients. Dyskinesia and parkinsonism are an integral part of the schizophrenia disease process whose relationship with other factors could be influenced by antipsychotic drug treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpsychires.2004.08.002 | DOI Listing |
J Neurol
September 2025
Department of Neurology, Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehakro Jongno-gu, Seoul, 03080, Republic of Korea.
Speech disorders differ between Parkinson's disease (PD) and multiple system atrophy (MSA), but studies focusing on group differences based on syllables or including cerebellar ataxia (CA) are lacking until now. This cross-sectional study aimed to analyze syllable-based speech characteristics in patients with PD, MSA, and CA, as well as healthy controls, to determine their diagnostic utility. Speech samples were collected from 68 PD, 52 MSA, 23 CA, and 70 healthy controls.
View Article and Find Full Text PDFBMJ Open
September 2025
Salisbury NHS Foundation Trust, Salisbury, UK.
Introduction: Difficulty with walking can lead to reduced quality of life for people with Parkinson's disease (pwPD); improving walking is considered a treatment priority. Drug therapies can control PD symptoms; however, pwPD often still experience mobility problems.Functional electrical stimulation (FES) induces movement in weak muscles via external electrical stimulation.
View Article and Find Full Text PDFBackground: Although levodopa remains the gold standard treatment for Parkinson's disease (PD), its chronic use is associated with levodopa-induced dyskinesia (LID), a motor complication that impacts prognosis, quality of life, and treatment costs. Most known LID-associated factors have been identified in European-descendant populations.
Objectives: To describe the epidemiology of LID in Latin American and Caribbean (LATAM) countries and assess the relevance of known and novel LID-associated factors in this population.
Neurol Ther
September 2025
Department of Neurology, The First Affiliated Hospital with Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China.
Introduction: The pathogenesis of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) remains uncertain. Our work sought to examine the cortical gyrification pattern and its corresponding functional connectivity alterations, along with the underlying neurotransmitter information, in LID of PD.
Methods: We included 30 PD patients with LID (PD-LID group), 30 without LID (PD-NLID group), and 30 age- and gender-matched healthy controls (HC group).
Parkinsonism Relat Disord
August 2025
Neurology Department, Coimbra University Hospital, Coimbra Local Health Unit, Portugal; Inherited Metabolic Disease Reference Center / MetabERN, Coimbra University Hospital, Coimbra Local Health Unit, Portugal.
Glucose transporter type 1 deficiency syndrome (GLUT1DS) is a disorder caused by variants in the SLC2A1 gene. Clinical features are heterogeneous, from the classic presentation to milder later-onset phenotypes. We describe the case of a male patient with adult-onset paroxysmal dyskinesia in a mild phenotype of GLUT1DS (NM_006516.
View Article and Find Full Text PDF